Hepatitis B Therapeutics Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Hepatitis B Therapeutics Market to 2027 - Global Analysis and Forecasts By Product Type ( Anti-Viral and Hepatitis B Vaccine ); Therapy ( Chemo Therapy, Immunosuppressant Therapy and Nucleoside Analogue ); Distribution Channel ( Hospital Pharmacies, Retail Pharmacies and Online Pharmacies ) and Geography

Report Code: TIPRE00003415 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Hepatitis B is a life threatening disease caused due to liver infection. Hepatitis B is said to cause chronic disorder even leading to death due to liver cirrhosis. Hepatitis B can be prevented by administration of hepatitis B vaccine. As per rules passed by the WHO, it is mandatory for infants to receive the hepatitis B vaccine as soon as possible after birth, most preferably within 24 hours. This helps in relatively reducing the risk of contracting hepatitis in the future.

MARKET DYNAMICS
The hepatitis B therapeutics market is anticipated to grow in the forecast period owing to driving factors such as increasing prevalence of hepatitis in infants as well as rising awareness regarding the disease. In addition, various R&D activities for the development of better vaccines for the treatment along with the availability of government initiatives are expected to offer significant growth opportunities in the market during the forecast period.

MARKET SCOPE
The "Global Hepatitis B Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of hepatitis B therapeutics market with detailed market segmentation by product type, therapy, distribution channel and geography. The global hepatitis B therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading hepatitis B therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global hepatitis B therapeutics market is segmented on the basis of product type, therapy and distribution channel. Based on product type, the market is segmented as anti-viral and hepatitis B vaccine. The hepatitis B therapeutics market, based on therapy is segmented into, chemo therapy, immunosuppressant therapy and nucleoside analogue. On the basis of distribution channel, the global hepatitis B therapeutics market is segmented into, hospital pharmacies, retail pharmacies and other pharmacies.


REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global hepatitis B therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The hepatitis B therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting hepatitis B therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the hepatitis B therapeutics market in these regions.

MARKET PLAYERS
The reports cover key developments in the hepatitis B therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from hepatitis B therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for hepatitis B therapeutics market in the global market. Below mentioned is the list of few companies engaged in the hepatitis B therapeutics market.

The report also includes the profiles of key hepatitis B therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

• GlaxoSmithKline plc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• VBI Vaccines Inc.
• Cipla Ltd
• Dynavax Technologies Corporation
• ContraVir Pharmaceuticals
• Other Companies

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Hepatitis B Therapeutics Market - By Product Type
1.3.2 Hepatitis B Therapeutics Market - By Therapy
1.3.3 Hepatitis B Therapeutics Market - By Distribution Channel
1.3.4 Hepatitis B Therapeutics Market - By Region
1.3.4.1 By Country

2. KEY TAKEWAYS

3. RESEARCH METHODOLOGY

4. HEPATITIS B THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. HEPATITIS B THERAPEUTICS MARKET - KEY MARKET DYNAMICS

5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. HEPATITIS B THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS

6.1. HEPATITIS B THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. HEPATITIS B THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. HEPATITIS B THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT TYPE

7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. ANTI-VIRAL
7.3.1. Overview
7.3.2. Anti-Viral Market Forecast and Analysis
7.3.3. Tenofovir Market
7.3.3.1. Overview
7.3.3.2. Tenofovir Market Forecast and Analysis
7.3.4. Entecavir Market
7.3.4.1. Overview
7.3.4.2. Entecavir Market Forecast and Analysis
7.4. HEPATITIS B VACCINE
7.4.1. Overview
7.4.2. Hepatitis B Vaccine Market Forecast and Analysis

8. HEPATITIS B THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPY

8.1. OVERVIEW
8.2. THERAPY MARKET FORECASTS AND ANALYSIS
8.3. CHEMO THERAPY
8.3.1. Overview
8.3.2. Chemo Therapy Market Forecast and Analysis
8.4. IMMUNOSUPPRESSANT THERAPY
8.4.1. Overview
8.4.2. Immunosuppressant Therapy Market Forecast and Analysis
8.5. NUCLEOSIDE ANALOGUE
8.5.1. Overview
8.5.2. Nucleoside Analogue Market Forecast and Analysis

9. HEPATITIS B THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. ONLINE PHARMACIES
9.5.1. Overview
9.5.2. Online Pharmacies Market Forecast and Analysis

10. HEPATITIS B THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA
10.1.1 North America Hepatitis B Therapeutics Market Overview
10.1.2 North America Hepatitis B Therapeutics Market Forecasts and Analysis
10.1.3 North America Hepatitis B Therapeutics Market Forecasts and Analysis - By Product Type
10.1.3.1. North America Antiviral Market Forecasts and Analysis - By Type
10.1.4 North America Hepatitis B Therapeutics Market Forecasts and Analysis - By Therapy
10.1.5 North America Hepatitis B Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Hepatitis B Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Hepatitis B Therapeutics Market
10.1.6.1.1 United States Hepatitis B Therapeutics Market by Product Type
10.1.6.1.1.1. United States Antiviral Market by Type
10.1.6.1.2 United States Hepatitis B Therapeutics Market by Therapy
10.1.6.1.3 United States Hepatitis B Therapeutics Market by Distribution Channel
10.1.6.2 Canada Hepatitis B Therapeutics Market
10.1.6.2.1 Canada Hepatitis B Therapeutics Market by Product Type
10.1.6.2.1.1. Canada Antiviral Market by Type
10.1.6.2.2 Canada Hepatitis B Therapeutics Market by Therapy
10.1.6.2.3 Canada Hepatitis B Therapeutics Market by Distribution Channel
10.1.6.3 Mexico Hepatitis B Therapeutics Market
10.1.6.3.1 Mexico Hepatitis B Therapeutics Market by Product Type
10.1.6.3.1.1. Mexico Antiviral Market by Type
10.1.6.3.2 Mexico Hepatitis B Therapeutics Market by Therapy
10.1.6.3.3 Mexico Hepatitis B Therapeutics Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Hepatitis B Therapeutics Market Overview
10.2.2 Europe Hepatitis B Therapeutics Market Forecasts and Analysis
10.2.3 Europe Hepatitis B Therapeutics Market Forecasts and Analysis - By Product Type
10.2.3.1. Europe Antiviral Market Forecasts and Analysis - By Type
10.2.4 Europe Hepatitis B Therapeutics Market Forecasts and Analysis - By Therapy
10.2.5 Europe Hepatitis B Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Hepatitis B Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Hepatitis B Therapeutics Market
10.2.6.1.1 Germany Hepatitis B Therapeutics Market by Product Type
10.2.6.1.1.1. Germany Antiviral Market by Type
10.2.6.1.2 Germany Hepatitis B Therapeutics Market by Therapy
10.2.6.1.3 Germany Hepatitis B Therapeutics Market by Distribution Channel
10.2.6.2 France Hepatitis B Therapeutics Market
10.2.6.2.1 France Hepatitis B Therapeutics Market by Product Type
10.2.6.2.1.1. France Antiviral Market by Type
10.2.6.2.2 France Hepatitis B Therapeutics Market by Therapy
10.2.6.2.3 France Hepatitis B Therapeutics Market by Distribution Channel
10.2.6.3 Italy Hepatitis B Therapeutics Market
10.2.6.3.1 Italy Hepatitis B Therapeutics Market by Product Type
10.2.6.3.1.1. Italy Antiviral Market by Type
10.2.6.3.2 Italy Hepatitis B Therapeutics Market by Therapy
10.2.6.3.3 Italy Hepatitis B Therapeutics Market by Distribution Channel
10.2.6.4 Spain Hepatitis B Therapeutics Market
10.2.6.4.1 Spain Hepatitis B Therapeutics Market by Product Type
10.2.6.4.1.1. Spain Antiviral Market by Type
10.2.6.4.2 Spain Hepatitis B Therapeutics Market by Therapy
10.2.6.4.3 Spain Hepatitis B Therapeutics Market by Distribution Channel
10.2.6.5 United Kingdom Hepatitis B Therapeutics Market
10.2.6.5.1 United Kingdom Hepatitis B Therapeutics Market by Product Type
10.2.6.5.1.1. United Kingdom Antiviral Market by Type
10.2.6.5.2 United Kingdom Hepatitis B Therapeutics Market by Therapy
10.2.6.5.3 United Kingdom Hepatitis B Therapeutics Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Hepatitis B Therapeutics Market Overview
10.3.2 Asia-Pacific Hepatitis B Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Hepatitis B Therapeutics Market Forecasts and Analysis - By Product Type
10.3.3.1. Asia Pacific Antiviral Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Hepatitis B Therapeutics Market Forecasts and Analysis - By Therapy
10.3.5 Asia-Pacific Hepatitis B Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Hepatitis B Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Hepatitis B Therapeutics Market
10.3.6.1.1 Australia Hepatitis B Therapeutics Market by Product Type
10.3.6.1.1.1. Australia Antiviral Market by Type
10.3.6.1.2 Australia Hepatitis B Therapeutics Market by Therapy
10.3.6.1.3 Australia Hepatitis B Therapeutics Market by Distribution Channel
10.3.6.2 China Hepatitis B Therapeutics Market
10.3.6.2.1 China Hepatitis B Therapeutics Market by Product Type
10.3.6.2.1.1. China Antiviral Market by Type
10.3.6.2.2 China Hepatitis B Therapeutics Market by Therapy
10.3.6.2.3 China Hepatitis B Therapeutics Market by Distribution Channel
10.3.6.3 India Hepatitis B Therapeutics Market
10.3.6.3.1 India Hepatitis B Therapeutics Market by Product Type
10.3.6.3.1.1. India Antiviral Market by Type
10.3.6.3.2 India Hepatitis B Therapeutics Market by Therapy
10.3.6.3.3 India Hepatitis B Therapeutics Market by Distribution Channel
10.3.6.4 Japan Hepatitis B Therapeutics Market
10.3.6.4.1 Japan Hepatitis B Therapeutics Market by Product Type
10.3.6.4.1.1. Japan Antiviral Market by Type
10.3.6.4.2 Japan Hepatitis B Therapeutics Market by Therapy
10.3.6.4.3 Japan Hepatitis B Therapeutics Market by Distribution Channel
10.3.6.5 South Korea Hepatitis B Therapeutics Market
10.3.6.5.1 South Korea Hepatitis B Therapeutics Market by Product Type
10.3.6.5.1.1. South Korea Antiviral Market by Type
10.3.6.5.2 South Korea Hepatitis B Therapeutics Market by Therapy
10.3.6.5.3 South Korea Hepatitis B Therapeutics Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Hepatitis B Therapeutics Market Overview
10.4.2 Middle East and Africa Hepatitis B Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Hepatitis B Therapeutics Market Forecasts and Analysis - By Product Type
10.4.3.1. Middle East and Africa Antiviral Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Hepatitis B Therapeutics Market Forecasts and Analysis - By Therapy
10.4.5 Middle East and Africa Hepatitis B Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Hepatitis B Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Hepatitis B Therapeutics Market
10.4.6.1.1 South Africa Hepatitis B Therapeutics Market by Product Type
10.4.6.1.1.1. South Africa Antiviral Market by Type
10.4.6.1.2 South Africa Hepatitis B Therapeutics Market by Therapy
10.4.6.1.3 South Africa Hepatitis B Therapeutics Market by Distribution Channel
10.4.6.2 Saudi Arabia Hepatitis B Therapeutics Market
10.4.6.2.1 Saudi Arabia Hepatitis B Therapeutics Market by Product Type
10.4.6.2.1.1. Saudi Arabia Antiviral Market by Type
10.4.6.2.2 Saudi Arabia Hepatitis B Therapeutics Market by Therapy
10.4.6.2.3 Saudi Arabia Hepatitis B Therapeutics Market by Distribution Channel
10.4.6.3 U.A.E Hepatitis B Therapeutics Market
10.4.6.3.1 U.A.E Hepatitis B Therapeutics Market by Product Type
10.4.6.3.1.1. U.A.E Antiviral Market by Type
10.4.6.3.2 U.A.E Hepatitis B Therapeutics Market by Therapy
10.4.6.3.3 U.A.E Hepatitis B Therapeutics Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Hepatitis B Therapeutics Market Overview
10.5.2 South and Central America Hepatitis B Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Hepatitis B Therapeutics Market Forecasts and Analysis - By Product Type
10.4.3.1. South and Central America Antiviral Market Forecasts and Analysis - By Type
10.5.4 South and Central America Hepatitis B Therapeutics Market Forecasts and Analysis - By Therapy
10.5.5 South and Central America Hepatitis B Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Hepatitis B Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Hepatitis B Therapeutics Market
10.5.6.1.1 Brazil Hepatitis B Therapeutics Market by Product Type
10.5.6.1.1.1. Brazil Antiviral Market by Type
10.5.6.1.2 Brazil Hepatitis B Therapeutics Market by Therapy
10.5.6.1.3 Brazil Hepatitis B Therapeutics Market by Distribution Channel
10.5.6.2 Argentina Hepatitis B Therapeutics Market
10.5.6.2.1 Argentina Hepatitis B Therapeutics Market by Product Type
10.5.6.2.1.1. Argentina Antiviral Market by Type
10.5.6.2.2 Argentina Hepatitis B Therapeutics Market by Therapy
10.5.6.2.3 Argentina Hepatitis B Therapeutics Market by Distribution Channel

11. INDUSTRY LANDSCAPE

11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. HEPATITIS B THERAPEUTICS MARKET, KEY COMPANY PROFILES

12.1. GLAXOSMITHKLINE PLC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. BRISTOL-MYERS SQUIBB COMPANY
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. F. HOFFMANN-LA ROCHE LTD
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. JOHNSON & JOHNSON
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. VBI VACCINES INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. CIPLA LTD
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. DYNAVAX TECHNOLOGIES CORPORATION
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. CONTRAVIR PHARMACEUTICALS
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments

13. APPENDIX

13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. GlaxoSmithKline plc.
2. Bristol-Myers Squibb Company
3. F. Hoffmann-La Roche Ltd
4. Johnson & Johnson
5. VBI Vaccines Inc.
6. Cipla Ltd
7. Dynavax Technologies Corporation
8. ContraVir Pharmaceuticals
9. Other Companies